NC H206

Requires health benefit plans that cover both oral and intravenous/injected anticancer drugs to provide coverage for oral anticancer drugs on a basis no less favorable than intravenous or injected alternatives.

Prohibits prior authorization, dollar limits, co-payments, coinsurance, deductibles, or other out-of-pocket expenses on oral anticancer drugs that do not also apply to intravenously administered or injected anticancer drugs.

Prevents insurers from achieving compliance by reclassifying anticancer drugs or increasing patient cost-sharing, and requires any increased out-of-pocket expenses on anticancer drugs to also apply to the majority of comparable medical or pharmaceutical benefits.

Effective January 1, 2018, for insurance contracts, policies, or amendments issued or renewed on or after that date.

Does not take effect if determined by the federal government to constitute a state-required benefit exceeding essential health benefits under federal regulations.